roniciclib: an antineoplastic agent that inhibits cyclin-dependent kinases; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 45380979 |
| CHEMBL ID | 4442620 |
| SCHEMBL ID | 875845 |
| MeSH ID | M0581850 |
| Synonym |
|---|
| 1223498-69-8 |
| bay-1000394 |
| roniciclib |
| bay10-00394 |
| SCHEMBL875845 |
| (2r,3r)-3-((2-((4-(cyclopropanesulfonimidoyl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)oxy)butan-2-ol |
| kb-145902 |
| gtpl7874 |
| bay 1000394 |
| bay 10-00394 |
| Q27088609 |
| (2r,3r)-3-[2-[4-(cyclopropylsulfonimidoyl)anilino]-5-(trifluoromethyl)pyrimidin-4-yl]oxybutan-2-ol |
| 1223498-26-7 |
| YYB49869 |
| C92605 |
| A858136 |
| TQP1629 |
| CHEMBL4442620 , |
| nsc-774911 |
| nsc774911 |
| bdbm50511926 |
| uelydgoojprwgf-mfohzaofsa-n |
| AKOS040742572 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Roniciclib combined with chemotherapy demonstrated an unfavorable risk-benefit profile in patients with extensive-disease SCLC, and the study was prematurely terminated." | ( Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First-Line Therapy in Patients with Extensive-Disease Small Cell Lung Cancer. Albert, I; Barlesi, F; Bidoli, P; Cadranel, J; Chung, J; Drews, U; Fritsch, A; Govindan, R; Horn, L; Juhász, E; Kowalski, D; Novello, S; Reck, M; Robinet, G; Wagner, A, 2019) | 0.51 |
| Excerpt | Relevance | Reference |
|---|---|---|
| "Two phase I dose-escalation studies evaluated two roniciclib dosing schedules: 3 days on/4 days off or 4 weeks on/2 weeks off." | ( Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies. Bahleda, R; Barlesi, F; Dy, GK; Govindan, R; Greillier, L; Grilley-Olson, JE; Henderson, D; Kornacker, M; Nogai, H; Ocker, M; Perol, M; Rajagopalan, P; Ray-Coquard, I; Schultheis, B; Soria, JC; Strumberg, D; Walter, AO; Weiss, GJ; Zalcman, G, 2017) | 0.46 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| PPM1D protein | Homo sapiens (human) | Potency | 20.8212 | 0.0052 | 9.4661 | 32.9993 | AID1347411 |
| Interferon beta | Homo sapiens (human) | Potency | 20.8212 | 0.0033 | 9.1582 | 39.8107 | AID1347411 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| NUAK family SNF1-like kinase 1 | Homo sapiens (human) | IC50 (µMol) | 0.0100 | 0.0013 | 0.2918 | 5.0900 | AID1845556 |
| Cyclin-T1 | Homo sapiens (human) | IC50 (µMol) | 0.0050 | 0.0010 | 0.5585 | 8.0000 | AID1317313; AID1549266; AID1653029; AID1868070 |
| Carbonic anhydrase 2 | Homo sapiens (human) | IC50 (µMol) | 10.0000 | 0.0002 | 1.1060 | 8.3000 | AID1239771; AID1868080 |
| Cyclin-dependent kinase 1 | Homo sapiens (human) | IC50 (µMol) | 0.0067 | 0.0004 | 1.3452 | 10.0000 | AID1239767; AID1317315; AID1549268; AID1653018; AID1696561; AID1845584; AID1890166 |
| Cyclin-dependent kinase 4 | Homo sapiens (human) | IC50 (µMol) | 0.0101 | 0.0006 | 0.5706 | 10.0000 | AID1317314; AID1549298; AID1653028; AID1696563; AID1845581; AID1868057; AID1890167 |
| G2/mitotic-specific cyclin-B1 | Homo sapiens (human) | IC50 (µMol) | 0.0070 | 0.0013 | 1.4518 | 10.0000 | AID1239767; AID1317315; AID1549268; AID1653018 |
| G1/S-specific cyclin-D1 | Homo sapiens (human) | IC50 (µMol) | 0.0110 | 0.0006 | 0.5479 | 9.5000 | AID1317314; AID1549298; AID1653028; AID1868057 |
| G1/S-specific cyclin-E1 | Homo sapiens (human) | IC50 (µMol) | 0.0092 | 0.0010 | 1.0404 | 10.0000 | AID1239768; AID1317298; AID1549269; AID1549270; AID1653019 |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | IC50 (µMol) | 0.0086 | 0.0004 | 1.0444 | 10.0000 | AID1239768; AID1317298; AID1549269; AID1653019; AID1696562; AID1845583; AID1890165 |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | IC50 (µMol) | 0.1630 | 0.0000 | 0.4830 | 8.8000 | AID1239769; AID1868076 |
| Cyclin-dependent kinase 7 | Homo sapiens (human) | IC50 (µMol) | 0.0210 | 0.0001 | 0.9106 | 9.2000 | AID1317353; AID1549265; AID1696566; AID1845580; AID1868068 |
| Cyclin-dependent kinase 9 | Homo sapiens (human) | IC50 (µMol) | 0.0050 | 0.0010 | 0.6236 | 8.0000 | AID1317313; AID1549266; AID1653029; AID1696567; AID1845579; AID1868070; AID1890144 |
| Cyclin-H | Homo sapiens (human) | IC50 (µMol) | 0.0250 | 0.0005 | 1.0823 | 9.2000 | AID1317353; AID1549265; AID1868068 |
| CDK-activating kinase assembly factor MAT1 | Homo sapiens (human) | IC50 (µMol) | 0.0250 | 0.0030 | 1.6892 | 9.2000 | AID1317353; AID1549265 |
| Cyclin-dependent kinase 3 | Homo sapiens (human) | IC50 (µMol) | 0.0070 | 0.0017 | 0.2026 | 2.2000 | AID1549270; AID1845582 |
| Cyclin-dependent-like kinase 5 | Homo sapiens (human) | IC50 (µMol) | 0.0100 | 0.0002 | 1.1832 | 10.0000 | AID1317312; AID1549271; AID1696564 |
| Cyclin-dependent kinase 5 activator 1 | Homo sapiens (human) | IC50 (µMol) | 0.0100 | 0.0010 | 1.2898 | 10.0000 | AID1317312; AID1549271 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1868054 | Inhibition of CDK1/Cyclin B (unknown origin) | 2022 | Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9 | From Structure Modification to Drug Launch: A Systematic Review of the Ongoing Development of Cyclin-Dependent Kinase Inhibitors for Multiple Cancer Therapy. |
| AID1549265 | Inhibition of recombinant human C-terminal His6-tagged full length CDK7/untagged recombinant full length human Cyclin H/N-terminal GST-tagged recombinant full length human MAT1 expressed in baculovirus infected Sf21 insect cells using cdk7 peptide as subs | 2019 | Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9 | Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update. |
| AID1868068 | Inhibition of CDK7/Cyclin H (unknown origin) | 2022 | Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9 | From Structure Modification to Drug Launch: A Systematic Review of the Ongoing Development of Cyclin-Dependent Kinase Inhibitors for Multiple Cancer Therapy. |
| AID1845579 | Inhibition of CDK9 (unknown origin) expressed in baculovirus-infected Sf9 insect cells | 2021 | Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1 | Development and Therapeutic Potential of NUAKs Inhibitors. |
| AID1317298 | Inhibition of human recombinant full length N-terminal GST-tagged CDK2 (1 to 298 residues)/cyclin E1 (1 to 395 residues) expressed in Sf9 insect cells using histone 3 as substrate by 33P-gamma ATP based assay | 2016 | Journal of medicinal chemistry, 10-13, Volume: 59, Issue:19 | Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy. |
| AID1696561 | Inhibition of CDK1 (unknown origin) | 2020 | Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22 | Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update. |
| AID1868079 | Inhibition of cell proliferation in human MCF7 cells | 2022 | Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9 | From Structure Modification to Drug Launch: A Systematic Review of the Ongoing Development of Cyclin-Dependent Kinase Inhibitors for Multiple Cancer Therapy. |
| AID1890165 | Inhibition of CDK2 (unknown origin) | 2022 | Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9 | Lessons Learned from Past Cyclin-Dependent Kinase Drug Discovery Efforts. |
| AID1653019 | Inhibition of recombinant GST-tagged human CDK2/cyclin E expressed in SF-9 cells after 10 mins in presence of [gamma-33P]ATP by scintillation counter analysis | 2019 | European journal of medicinal chemistry, Feb-15, Volume: 164 | Recent development of CDK inhibitors: An overview of CDK/inhibitor co-crystal structures. |
| AID1845556 | Inhibition of NUAK1 (unknown origin) | 2021 | Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1 | Development and Therapeutic Potential of NUAKs Inhibitors. |
| AID1549270 | Inhibition of recombinant human full-length C-terminal His6-tagged CDK3/full-length human N-terminal GST-tagged Cyclin E expressed in baculovirus infected Sf21 insect cells using histone H1 as substrate | 2019 | Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9 | Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update. |
| AID1549271 | Inhibition of human recombinant full-length N-terminal His6-tagged CDK5/recombinant human full-length N-terminal GST-tagged p35 using histone H1 as substrate | 2019 | Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9 | Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update. |
| AID1317314 | Inhibition of recombinant human N-terminal GST-tagged CDK4/cyclin D1 expressed in baculovirus infected sf cells | 2016 | Journal of medicinal chemistry, 10-13, Volume: 59, Issue:19 | Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy. |
| AID1549268 | Inhibition of recombinant human N-terminal GST/His6-tagged CDK1 (M1 to M297 residues)/Cyclin B1 (M1 to V433 residues) expressed in baculovirus infected Sf9 insect cells using histone 3s as substrate in presence of [gamma-33P] ATP | 2019 | Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9 | Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update. |
| AID1239767 | Inhibition of recombinant CDK1/GST-fused cyclin B (unknown origin) expressed in baculovirus infected insect Sf9 cells by substrate phosphorylation assay in presence of [33P]-gamma adenosine triphosphate | 2015 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17 | Cyclin dependent kinase (CDK) inhibitors as anticancer drugs. |
| AID1845581 | Inhibition of CDK4 (unknown origin) expressed in baculovirus-infected Sf9 insect cells | 2021 | Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1 | Development and Therapeutic Potential of NUAKs Inhibitors. |
| AID1868080 | Inhibition of CA-II (unknown origin) | 2022 | Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9 | From Structure Modification to Drug Launch: A Systematic Review of the Ongoing Development of Cyclin-Dependent Kinase Inhibitors for Multiple Cancer Therapy. |
| AID1696566 | Inhibition of CDK7 (unknown origin) | 2020 | Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22 | Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update. |
| AID1845582 | Inhibition of CDK3 (unknown origin) expressed in baculovirus-infected Sf9 insect cells | 2021 | Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1 | Development and Therapeutic Potential of NUAKs Inhibitors. |
| AID1549266 | Inhibition of recombinant human full-length C-terminal His6-tagged CDK9/human full-length untagged cyclin T1 expressed in baculovirus infected Sf21 insect cells using PDKtide as substrate | 2019 | Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9 | Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update. |
| AID1239768 | Inhibition of recombinant CDK2/GST-fused cyclin E (unknown origin) expressed in baculovirus infected insect Sf9 cells by substrate phosphorylation assay in presence of [33P]-gamma adenosine triphosphate | 2015 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17 | Cyclin dependent kinase (CDK) inhibitors as anticancer drugs. |
| AID1845584 | Inhibition of CDK1 (unknown origin) expressed in baculovirus-infected Sf9 insect cells | 2021 | Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1 | Development and Therapeutic Potential of NUAKs Inhibitors. |
| AID1696563 | Inhibition of CDK4 (unknown origin) | 2020 | Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22 | Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update. |
| AID1653029 | Inhibition of CDK9/Cyclin T1 (unknown origin) | 2019 | European journal of medicinal chemistry, Feb-15, Volume: 164 | Recent development of CDK inhibitors: An overview of CDK/inhibitor co-crystal structures. |
| AID1653018 | Inhibition of recombinant GST-tagged human CDK1/cyclin B expressed in SF-9 cells after 10 mins in presence of [gamma-33P]ATP by scintillation counter analysis | 2019 | European journal of medicinal chemistry, Feb-15, Volume: 164 | Recent development of CDK inhibitors: An overview of CDK/inhibitor co-crystal structures. |
| AID1845580 | Inhibition of CDK7 (unknown origin) expressed in baculovirus-infected Sf9 insect cells | 2021 | Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1 | Development and Therapeutic Potential of NUAKs Inhibitors. |
| AID1239770 | Cytotoxicity against human MCF7 cells assessed as growth inhibition after 96 hrs | 2015 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17 | Cyclin dependent kinase (CDK) inhibitors as anticancer drugs. |
| AID1696562 | Inhibition of CDK2 (unknown origin) | 2020 | Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22 | Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update. |
| AID1239769 | Inhibition of VEGFR2 (unknown origin) | 2015 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17 | Cyclin dependent kinase (CDK) inhibitors as anticancer drugs. |
| AID1317315 | Inhibition of human recombinant N-terminal GST/HIS6-tagged CDK1 (1 to 297 residues)/cyclin B1 (1 to 433 residues) expressed in baculovirus infected Sf9 insect cells using histone 3 as substrate by 33P-gamma ATP based assay | 2016 | Journal of medicinal chemistry, 10-13, Volume: 59, Issue:19 | Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy. |
| AID1868057 | Inhibition of CDK4/Cyclin D1 (unknown origin) | 2022 | Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9 | From Structure Modification to Drug Launch: A Systematic Review of the Ongoing Development of Cyclin-Dependent Kinase Inhibitors for Multiple Cancer Therapy. |
| AID1890144 | Inhibition of CDK9 (unknown origin) | 2022 | Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9 | Lessons Learned from Past Cyclin-Dependent Kinase Drug Discovery Efforts. |
| AID1317312 | Inhibition of recombinant human full length N-terminal His6-tagged CDK5/N-terminal GST-tagged p25 expressed in baculovirus infected Sf21 insect cells using histone H1 as substrate | 2016 | Journal of medicinal chemistry, 10-13, Volume: 59, Issue:19 | Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy. |
| AID1890166 | Inhibition of CDK1 (unknown origin) | 2022 | Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9 | Lessons Learned from Past Cyclin-Dependent Kinase Drug Discovery Efforts. |
| AID1549298 | Inhibition of recombinant human N-terminal GST-tagged CDK4/Cyclin D1 expressed in baculovirus infected Spodoptera frugiperda insect cells using pRb as substrate | 2019 | Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9 | Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update. |
| AID1696567 | Inhibition of CDK9 (unknown origin) | 2020 | Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22 | Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update. |
| AID1653027 | Antiproliferative activity against human MCF7 cells after 4 days by crystal violet staining based assay | 2019 | European journal of medicinal chemistry, Feb-15, Volume: 164 | Recent development of CDK inhibitors: An overview of CDK/inhibitor co-crystal structures. |
| AID1868056 | Inhibition of CDK2/Cyclin E (unknown origin) | 2022 | Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9 | From Structure Modification to Drug Launch: A Systematic Review of the Ongoing Development of Cyclin-Dependent Kinase Inhibitors for Multiple Cancer Therapy. |
| AID1653028 | Inhibition of CDK4/Cyclin D1 (unknown origin) | 2019 | European journal of medicinal chemistry, Feb-15, Volume: 164 | Recent development of CDK inhibitors: An overview of CDK/inhibitor co-crystal structures. |
| AID1239771 | Inhibition of carbonic anhydrase-2 (unknown origin) | 2015 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17 | Cyclin dependent kinase (CDK) inhibitors as anticancer drugs. |
| AID1696564 | Inhibition of CDK5 (unknown origin) | 2020 | Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22 | Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update. |
| AID1868070 | Inhibition of CDK9/Cyclin T1 (unknown origin) | 2022 | Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9 | From Structure Modification to Drug Launch: A Systematic Review of the Ongoing Development of Cyclin-Dependent Kinase Inhibitors for Multiple Cancer Therapy. |
| AID1845583 | Inhibition of CDK2 (unknown origin) expressed in baculovirus-infected Sf9 insect cells | 2021 | Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1 | Development and Therapeutic Potential of NUAKs Inhibitors. |
| AID1317353 | Inhibition of recombinant human full length C-terminal His6-tagged CDK7/cyclin H/N-terminal GST-tagged MAT1 expressed in baculovirus infected Sf21 insect cells using cdk7 substrate peptide | 2016 | Journal of medicinal chemistry, 10-13, Volume: 59, Issue:19 | Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy. |
| AID1549269 | Inhibition of recombinant human N-terminal thrombin cleavage site-fused/GST-tagged CDK2 (M1 to L298 residues)/Cyclin E1 (M1 to A395 residues) expressed in baculovirus infected Sf9 insect cells using histone 3s as substrate in presence of [gamma-33P] ATP | 2019 | Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9 | Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update. |
| AID1868076 | Inhibition of VEGFR2 (unknown origin) | 2022 | Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9 | From Structure Modification to Drug Launch: A Systematic Review of the Ongoing Development of Cyclin-Dependent Kinase Inhibitors for Multiple Cancer Therapy. |
| AID1890167 | Inhibition of CDK4 (unknown origin) | 2022 | Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9 | Lessons Learned from Past Cyclin-Dependent Kinase Drug Discovery Efforts. |
| AID1317313 | Inhibition of recombinant human full length C-terminal His6-tagged CDK9/cyclin T1 expressed in baculovirus infected Sf21 insect cells using PDKtide as substrate | 2016 | Journal of medicinal chemistry, 10-13, Volume: 59, Issue:19 | Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy. |
| AID1347412 | qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1345612 | Human cyclin dependent kinase 2 (CDK1 subfamily) | 2013 | ChemMedChem, Jul, Volume: 8, Issue:7 | The lab oddity prevails: discovery of pan-CDK inhibitor (R)-S-cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide (BAY 1000394) for the treatment of cancer. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 13 (68.42) | 24.3611 |
| 2020's | 6 (31.58) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (16.66) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (10.53%) | 5.53% |
| Reviews | 8 (42.11%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (47.37%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||